CN105477030A - Phosphatidylserine and gamma aminobutyric acid compound preparation special for astronaut - Google Patents
Phosphatidylserine and gamma aminobutyric acid compound preparation special for astronaut Download PDFInfo
- Publication number
- CN105477030A CN105477030A CN201510981040.3A CN201510981040A CN105477030A CN 105477030 A CN105477030 A CN 105477030A CN 201510981040 A CN201510981040 A CN 201510981040A CN 105477030 A CN105477030 A CN 105477030A
- Authority
- CN
- China
- Prior art keywords
- phosphatidylserine
- aminobutyric acid
- gamma aminobutyric
- gaba
- astronaut
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutanoic acid Natural products NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 title claims abstract description 66
- 229960003692 gamma aminobutyric acid Drugs 0.000 title claims abstract description 53
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 title claims abstract description 24
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 title claims abstract description 20
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- -1 gamma aminobutyric acid compound Chemical class 0.000 title claims abstract description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 18
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 9
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 9
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000010356 sorbitol Nutrition 0.000 claims abstract description 9
- 239000000600 sorbitol Substances 0.000 claims abstract description 9
- 239000000811 xylitol Substances 0.000 claims abstract description 9
- 235000010447 xylitol Nutrition 0.000 claims abstract description 9
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 9
- 229960002675 xylitol Drugs 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 6
- 239000007935 oral tablet Substances 0.000 claims 1
- 229940096978 oral tablet Drugs 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 abstract description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 6
- 235000012000 cholesterol Nutrition 0.000 abstract description 3
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract description 2
- 230000036651 mood Effects 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 235000020767 valerian extract Nutrition 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 description 17
- 230000035882 stress Effects 0.000 description 15
- 238000011160 research Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000002490 cerebral effect Effects 0.000 description 8
- 230000008451 emotion Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 201000006474 Brain Ischemia Diseases 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 206010015037 epilepsy Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000005915 GABA Receptors Human genes 0.000 description 3
- 108010005551 GABA Receptors Proteins 0.000 description 3
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- 206010039966 Senile dementia Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102000004121 Annexin A5 Human genes 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229960002163 hydrogen peroxide Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 229960003753 nitric oxide Drugs 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 208000027691 Conduct disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000027484 GABAA receptors Human genes 0.000 description 1
- 108091008681 GABAA receptors Proteins 0.000 description 1
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 1
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000228347 Monascus <ascomycete fungus> Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 201000009916 Postpartum depression Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000792914 Valeriana Species 0.000 description 1
- 241000792902 Valerianaceae Species 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000030120 acrosome reaction Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 230000002450 orbitofrontal effect Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 230000008010 sperm capacitation Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000002438 stress hormone Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 235000017468 valeriana Nutrition 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a phosphatidylserine and gamma aminobutyric acid compound preparation special for an astronaut. The compound reparation is prepared from the following raw materials: phosphatidylserine, gamma aminobutyric acid, a valerian extract, sorbitol, xylitol and magnesium stearate. The compound preparation provided by the invention can effectively prevent and treat psychological stress of the astronaut, keep and improve the cognitive function of the astronaut, and adjust mood; in addition, the compound preparation also can be used for reducing cholesterol, preventing cardiovascular disease, resisting inflammation and cancer, and boosting immunity.
Description
Technical field
The present invention relates to a kind of pharmaceutical formulation, particularly one is for spacefarer during space flight, prevents and treats the psychological stress of spacefarer, maintenance and improves the cognitive function of spacefarer, the pharmaceutical formulation regulating emotion and production technology.
Background technology
Research under manned space flight practice and ground simulation environment shows, be in the space extreme environment differed widely with earth environment for a long time, the psychology of people and emotion can be made to produce obstacle, conduct disorder, task performance reduction, even may cause satisfactorily cannot completing aerial mission.Along with the manned space flight time is more and more longer and aerial mission is day by day complicated, " psychology ensures " concept enters aerospace medicine field.Being in for a long time can with the behavior of people and the change of task performance in weightlessness, small space, noisy environment.Such change main manifestations is the obstacle in psychology or emotion, as AOI narrow, motivation and level of activation reductions, emotional lability, depression, indifferently and asthenia.The feature of the psychosocial adjustment's process disorder that also comprises sleep, memory and focus one's attention in these cases.These negative reactions in space travel constitute the risk factor reducing occupants' psychology and behavior reliability also can damage being successfully completed of its aerial mission.Therefore be necessary to research and develop the psychological stress of a kind of spacefarer of control, maintenance and improve the cognitive function of spacefarer, regulate the pharmaceutical formulation of emotion.
Summary of the invention
The object of this invention is to provide a kind of for spacefarer during space flight, prevent and treat the psychological stress of spacefarer, maintenance and improve the cognitive function of spacefarer, the pharmaceutical formulation of adjustment emotion, main composition is made up of Phosphatidylserine, gamma aminobutyric acid, Rhizoma et radix valerianae extract.
In order to realize object of the present invention, the special Phosphatidylserine gamma aminobutyric acid compound formulation of a kind of spacefarer is made up of following raw materials according: Phosphatidylserine, gamma aminobutyric acid, Rhizoma et radix valerianae extract, Sorbitol, xylitol, magnesium stearate.The component raw material weight ratio of said preparation is as follows:
Phosphatidylserine 20% ~ 40%
Gamma aminobutyric acid 10% ~ 30%
Rhizoma et radix valerianae extract 10% ~ 20%
Sorbitol 15% ~ 38%
Xylitol 10% ~ 20%
Magnesium stearate 0.1% ~ 1.5%
Preferably:
Phosphatidylserine 30%
Gamma aminobutyric acid 25%
Rhizoma et radix valerianae extract 10%
Sorbitol 24%
Xylitol 10%
Magnesium stearate 1%
Concrete production technology is as follows:
Phosphatidylserine, gamma aminobutyric acid, Rhizoma et radix valerianae extract are inserted blender mixing by certain material rate, in mixed process, pelletize is sprayed with fine mist with the edible ethanol of 40 ~ 80%, cross 10 ~ 60 mesh sieves, dry at 60 ~ 90 DEG C, then add Sorbitol in proportion, xylitol, magnesium stearate fully mix, be pressed into the tablet of certain specification.
The Phosphatidylserine gamma aminobutyric acid compound formulation that a kind of spacefarer provided by the invention is special, the physiological function of main component Phosphatidylserine is as follows:
1) Improving memory power, delay brain fag, treatment senile dementia
Senile dementia has become problem very important in world wide, and it has become the fourth-largest disease of old people.Even seriously do not arrive senile dementia, general people is after the middle age, memory also can serious decline cause the main cause of disease to be that brain is old and feeble along with the aging of health, certain period has been arrived when the age, in brain, the content of cholesterol will increase, the content comprising some important phospholipid of Phosphatidylserine then can correspondingly reduce, this chemical change causes in human cell membrane, the decline of enzymatic activity and transport capacity, nerve synapse is also in minimizing simultaneously, and the memory of brain will decrease.Phosphatidylserine can regulate the ratio of the C/PL in brain, recovers normal flow and the chemical composition of brain cell membrane, activating brain cell, improves the activity of organized enzyme in brain, memory reinforcing.
2) stress is alleviated
Nowadays brain overwork and the brain fag caused has become a kind of commonplace health problem, the depression caused by brain overwork has become the primary killers of the new century mankind, research shows, Phosphatidylserine significantly can reduce the level being engaged in stress hormone too much in people's body of tense working, visual cognitive ability, stepping up vigilance property and memory can be promoted, improper release emotion.
3) brain injury, treatment childhood hyperkinetic syndrome is repaired
Phosphatidylserine is a kind of main component of nerve, can in nutrition and activation brain various enzyme activity, slow down neurotransmitter minimizing, to repair cerebral lesion outside cell by being turned to, removing harmful substance, improve attention, concentrate one's energy, improved dynamic state.Research shows, brain neurotransmitter lazy weight can reduce the suppression activity of central nervous system, and the action of child is increased.Phosphatidylserine is a kind of important nerve component, energy nutrition brain composition, the various relevant enzymes material of activation brain, and then slows down this generation producing the phenomenon of hyperkinetic syndrome due to brain neurotransmitter lazy weight.
The physiological function of main component gamma aminobutyric acid is as follows:
1) reduce blood pressure
Hypertension is one of main cause causing cardiovascular and cerebrovascular disease.According to statistics, the disease death number that the whole world causes because of hypertension every year surpasses 1,200 ten thousand.Gamma aminobutyric acid (GABA) is one of main constituent of a lot of blood pressure-reducing food; Important hypotensive activity composition in the Chinese medicines such as monascus, the Radix Astragali and Radix Hedysari is also GABA.Have GABA can innervation system in mammal cerebrovascular, and there is GABA receptor, GABA with play the GABAA receptor of blood vessel dilating effect and have inhibiting GABAB receptor to combine to SNE, promotion vasodilation, reduces blood pressure.Angiotensin I hydrolysis is generated Angiotensin II by Angiotensin-Converting (ACE), thus causes vasoconstriction, and blood pressure raises; The inside and outside experiment of body all proves that GABA and metabolite γ hydroxybutyric acid (GHBA) thereof can suppress ACE active.
2) anxiety and depression
Research is had to point out effect of GABA tool anxiety, antidepressant and mood of releiving.Research proves that in patients with depression blood plasma, cerebrospinal fluid and cerebral tissue, GABA content declines, and in orbitofrontal cortex, GABA neuronal quantity reduces; In patients with postpartum depression cortex, GABA content declines; Patients with depression treatment back brain GABA content raises.
3) improving water flood, raising memory
After the oral GABA of people, time for falling asleep shortens, and extends S sleep II phase and REM sleep phase after experiment shows to take GABA.Research is also had to point out that GABA effectively can treat infant night crying due to fright in infant at night syndrome.In addition, more existing short dormancy medicines play effect by the affinity increasing GABA receptor just.Also there are some medicines to decompose to improve its content in brain by suppressing GABA, increase the S sleep time to a certain extent.Multinomial animal and human group experiment points out that GABA can memory reinforcing, thinks that GABA is the effect of long-term accumulated to the reinforced effects that people's memory is potential at present.
4) prevention and therapy of the sacred diseases such as epilepsy is participated in
GABA can play a crucial role in the generation of epilepsy in mediator infringement, and in regulation and control brain, GABA system is one of effective way controlling epilepsy.In the epileptic patient cerebral tissue focus of excision, GABA level significantly reduces.Because GABA is more weak by blood brain barrier ability, therefore can not relies on GABA and carry out epilepsy therapy, now synthesize many GABA derivants (being strengthened by the ability of modifying laggard people's blood brain barrier) and used as the medicine for the treatment of epilepsy.The shortage of some other nervous system disease and GABA also has certain dependency.Experiment finds that the generation of all kinds of convulsions all declines relevant to GABA content in cerebral tissue.In parkinson patient spinal cord, GABA content is also lower, and part research points out that GABA and parkinson disease process exist relation.
5) effect in reproductive system
Motion and the steroid hormone of GABA and mankind spermatozoon produce relevant.Research finds that sperm membrane surface exists GABA receptor; And rat tunica mucosa tubae uterinae organizes GABA content high, infer that GABA is relevant with spermatiation.Experiment in vitro is pointed out, GABA can significantly strengthen capacitation and acrosome reaction, promotes that spermatiation is sent out.In addition, what GABA also significantly can promote human spermatogoa wears ovum ability, improves rate of fertilization.
6) Detoxication
GABA suppresses glutamic acid decarboxylase, impels more glutamic acid to be combined with ammonia to generate carbamide to excrete, and reduces ammonia concentration malicious to remove ammonia; In addition GABA also has the function of relieving alcohol to neuroblast toxicity.
The physiological function of main component Rhizoma et radix valerianae extract is as follows:
Rhizoma et radix valerianae is Valerianaceae valeriana herbaceos perennial, research shows, the active component of Rhizoma et radix valerianae has alkaloid, volatile oil, flavonoid etc., and have the effects such as tranquillizing and allaying excitement, relieving spasm to stop pain, increase coronary flow, arrhythmia, its root uses as dietary supplement.
The present invention uses Phosphatidylserine, gamma aminobutyric acid, Rhizoma et radix valerianae extract three kinds of combination of active principles, mutually works in coordination with, can the psychological stress of effectively preventing spacefarer, maintenance and improve spacefarer cognitive function, regulate emotion; In addition invention formulation also can be used for reducing that cholesterol, angiocardiopathy preventing, antiinflammatory are anticancer, enhancing immunity.
Detailed description of the invention:
The raw material of the present embodiment tablet is as follows:
Phosphatidylserine 30%
Gamma aminobutyric acid 25%
Rhizoma et radix valerianae extract 10%
Sorbitol 24%
Xylitol 10%
Magnesium stearate 1%
Phosphatidylserine, gamma aminobutyric acid, Rhizoma et radix valerianae extract are inserted blender mixing by certain material rate, in mixed process, pelletize is sprayed with fine mist with the edible ethanol of 60%, cross 20 mesh sieves, dry at 80 DEG C, then add Sorbitol in proportion, xylitol, magnesium stearate fully mix, be pressed into the tablet of heavy 1 gram.
Animal experiment is carried out with said preparation:
Test one:
Test objective: study cognitive function explored by this preparation improvement result to global cerebral ischemia-reperfusion mice.
Test method: adopt the temporary blocking-up bilateral carotid of Himori method improved to prepare focal cerebral ischemia-Reperfusion injury wound model, carry out explorative experiment and Jumping test, observe and fill with cognitive function explored by this preparation of food improvement result to global cerebral ischemia-reperfusion mice, and to nitric oxide (nitricoxide in each dosage group Mice brain tissues and blood, NO) content and nitricoxide synthase (nitricoxidesynthase, NOS) hydrogen peroxide (hydrogenperoxide, H in vigor, cerebral tissue
2o
2) content and catalase (catalase, CAT) vigor measure, and measure cerebral index.
Result of the test: this preparation can improve the exploration cognitive dysfunction caused by Brain Ischemia-reperfusion Injury; Reduce NO and HO content, reduce NOS vigor, improve CAT vigor and increase cerebral index.
Conclusion (of pressure testing): this preparation is explored cognitive function to Brain Ischemia-reperfusion Injury mice and is improved effect, its mechanism of action is by reducing NOS vigor and strengthening CAT vigor, improve cerebral tissue to the Scavenging activity of oxygen-derived free radicals, thus alleviate the brain tissue impairment that ischemia-reperfusion causes.
Test two:
Test objective: inquiring into trained reflex case stress the destruction of different time on mouse chest cell and the impact of apoptosis, is intervened by this preparation, discloses this preparation to stress the regulating action of caused changes in immune function.
Test method: utilize the Stress model that spare part reflective box is brought out, observing stress the changing condition of thymus function after 3,5,7 days and the intervention of this preparation.
Result of the test: stress organize for 3,5,7 days the two positive cell of mouse thymus weight, thymus index, glucocorticoid levels, FFAR19 albumen mean fluorescence, the mono-positive cell of Annexin-V and Annexin-V with PI have compared with matched group significant difference (
p< 0.05).
Conclusion (of pressure testing): spare part reflective box stress be a kind of acute Negative Emotional stress, stress character milder.Thymus function stress be affected, this preparation scalable stress and the damage of thymus is shielded by neuroendocrine-immune network.
Claims (2)
1. the Phosphatidylserine gamma aminobutyric acid compound formulation that spacefarer is special, is characterized in that: be with Phosphatidylserine, gamma aminobutyric acid for primary raw material, be aided with Sorbitol, oral tablet that xylitol, magnesium stearate are made.
2. the Phosphatidylserine gamma aminobutyric acid compound formulation that a kind of spacefarer according to claim 1 is special, is characterized in that: the component raw material weight ratio of said preparation is as follows:
Phosphatidylserine 20% ~ 40%
Gamma aminobutyric acid 10% ~ 30%
Rhizoma et radix valerianae extract 10% ~ 20%
Sorbitol 15% ~ 38%
Xylitol 10% ~ 20%
Magnesium stearate 0.1% ~ 1.5%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510981040.3A CN105477030A (en) | 2015-12-24 | 2015-12-24 | Phosphatidylserine and gamma aminobutyric acid compound preparation special for astronaut |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510981040.3A CN105477030A (en) | 2015-12-24 | 2015-12-24 | Phosphatidylserine and gamma aminobutyric acid compound preparation special for astronaut |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105477030A true CN105477030A (en) | 2016-04-13 |
Family
ID=55664545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510981040.3A Pending CN105477030A (en) | 2015-12-24 | 2015-12-24 | Phosphatidylserine and gamma aminobutyric acid compound preparation special for astronaut |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105477030A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107997152A (en) * | 2017-11-24 | 2018-05-08 | 南通励成生物工程有限公司 | A kind of preparation method of nutrient composition, health products and health products |
| CN108497493A (en) * | 2018-04-04 | 2018-09-07 | 沈阳姿上元生物科技有限责任公司 | A kind of food and preparation method thereof improving cranial nerve cell function |
| CN109198607A (en) * | 2017-07-03 | 2019-01-15 | 北京神飞航天应用技术研究院 | A kind of nutritious food preparation that can improve spacefarer's memory |
-
2015
- 2015-12-24 CN CN201510981040.3A patent/CN105477030A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109198607A (en) * | 2017-07-03 | 2019-01-15 | 北京神飞航天应用技术研究院 | A kind of nutritious food preparation that can improve spacefarer's memory |
| CN107997152A (en) * | 2017-11-24 | 2018-05-08 | 南通励成生物工程有限公司 | A kind of preparation method of nutrient composition, health products and health products |
| CN108497493A (en) * | 2018-04-04 | 2018-09-07 | 沈阳姿上元生物科技有限责任公司 | A kind of food and preparation method thereof improving cranial nerve cell function |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Papez | A proposed mechanism of emotion | |
| Aalbers et al. | Animal models for vagus nerve stimulation in epilepsy | |
| Golechha et al. | Hydroalcoholic extract of Emblica officinalis Gaertn. affords protection against PTZ-induced seizures, oxidative stress and cognitive impairment in rats | |
| WO2003013549A2 (en) | Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals | |
| Nesterova et al. | Anxiolytic activity of diterpene alkaloid songorine | |
| CN105477030A (en) | Phosphatidylserine and gamma aminobutyric acid compound preparation special for astronaut | |
| Ghisoni et al. | Neopterin acts as an endogenous cognitive enhancer | |
| Szabó et al. | High-frequency burst vagal nerve simulation therapy in a natural primate model of genetic generalized epilepsy | |
| Liu et al. | Stimulation of the anterior nucleus of the thalamus induces changes in amino acids in the hippocampi of epileptic rats | |
| Xie et al. | Neuropeptide S counteracts paradoxical sleep deprivation-induced anxiety-like behavior and sleep disturbances | |
| Sailesh et al. | Can controlled vestibular stimulation reduce stress | |
| Darbandi et al. | Kaempferol promotes memory retention and density of hippocampal CA1 neurons in intra-cerebroventricular STZ-induced experimental AD model in Wistar rats | |
| Ciric et al. | Alterations of sleep and sleep oscillations in the hemiparkinsonian rat | |
| Piechal et al. | Influence of long-term zinc administration on spatial learning and exploratory activity in rats | |
| Rosa et al. | Transcranial magnetic stimulation: review of accidental seizures | |
| Frohmann et al. | Psychophysiologische Effekte atmosphärischer Qualitäten der Landschaft| Psychophysiological effects of landscape's atmospheric qualities | |
| Slawecki et al. | Neonatal nicotine exposure alters hippocampal EEG and event-related potentials (ERPs) in rats | |
| CN107412244A (en) | Purposes of the albiflorin in the product for improving epiphysin systemic-function is prepared | |
| Sharp et al. | Options for pharmacoresistant epilepsy in children: when medications don’t work | |
| Sahini et al. | Environmental enrichment improves cognitive function, learning, memory and anxiety-related behaviours in rodent models of dementia: implications for future study | |
| Valdés-Cruz et al. | Long-term changes in sleep and electroencephalographic activity by chronic vagus nerve stimulation in cats | |
| Previc | Dopamine, altered consciousness, and distant space with special reference to shamanic ecstasy | |
| Branchey et al. | The effect of alpha-methyl-para-tyrosine on sleep and arousal in the rat | |
| Drake et al. | Integrative medicine in traumatic brain injury | |
| WO2015018471A1 (en) | Pni (psychoneuroimmunium) lobbyist cell protection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160413 |